(redirected from Antibody-dependent cell-mediated cytotoxicity)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to Antibody-dependent cell-mediated cytotoxicity: antibody-dependent cell-mediated cytotoxicity (ADCC)
ADCCAntibody-Dependent Cellular Cytotoxicity
ADCCAntibody-Dependent Cell-Mediated Cytotoxicity
ADCCAbu Dhabi Combat Club (wrestling)
ADCCAdenoid Cystic Carcinoma (gland tumor)
ADCCAdvertising and Design Club of Canada (Toronto, Ontario, Canada)
ADCCAlzheimer's Disease Core Center
ADCCAdrenocortical Carcinoma
ADCCAir Defense Control Center
ADCCAvoiding Dangerous Climate Change (conference)
ADCCAutomated Dispensing Cabinet (drug dispensing)
ADCCAsia-Pacific Development Communication Centre (Dhurakij Pundit University; Bangkok, Thailand)
ADCCArctic System Science Data Coordination Center (ARCSS)
ADCCAntibody Dependent Cytotoxic Cell
ADCCAdvanced Data Communication Control
ADCCAir Defense Command & Control
ADCCAsynchronous Data Communications Controller
ADCCAccess Data Consulting Corporation (Greenwood Village, CO)
ADCCAir Defense Coordination Center
ADCCAssociation des Descendants de Capitaines Corsaires (France)
ADCCAbu Dhabi Construction Company (United Arab Emirates)
ADCCAdmiral Drake Cricket Club (UK)
ADCCANZAC (Australian and New Zealand Army Corps) Day Commemoration Committee (Australia)
ADCCAlzheimer's Disease Care Clinic
References in periodicals archive ?
Glycoengineered alemtuzumab, made in CHO cells transfected with glycosyltransferases to change glycosylation to being more comparable to that of production in rat cells, showed higher antibody-dependent cell-mediated cytotoxicity compared to the wild type drug.
ALT-803 also potently activates NK cells and enhances antibody-dependent cell-mediated cytotoxicity of antibodies in various experimental models.
Using Xencor's XmAb Fc enhancement technology, MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumour cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.
Full browser ?